Vancouver, British Columbia – January 25, 2016 – Sirona Biochem Corp. (TSX-V: SBM / FSE: ZSB), announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 – 10 in San Francisco, California.
Sirona’s Chief Business Development Officer, Attila Hajdu, will communicate the current state of the Company’s pipeline and future strategy in addition to participating in follow up meetings with key investors and leading companies in the pharmaceutical and cosmetic industries. The Canadian Technology Accelerator program is a new conference feature this year that identifies areas of potential collaboration for Sirona’s platform technology of fluorination chemistry.
“We are extremely happy to be invited back to the Dose of the Valley and look forward to exploring new growth opportunities” said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “Sirona has an innovative platform technology that can be applied to develop new compounds in areas of unmet needs, and we have already begun to explore strategic partnerships with big pharma to unlock the potential value in new opportunities.”
About Dose of the Valley
The two-day program organized by the C100 (www.thec100.org), BDC Venture Capital (www.bdc.ca) and the San Francisco Consulate is designed to connect Canada’s most promising biopharma, medical device, and health IT companies with key players from within the Bay Area and Silicon Valley. Dose of the Valley will facilitate face-to-face interaction with investors, technology scouts, mentors, and industry experts. The program provides an opportunity to gain visibility and develop productive relationships within this vibrant ecosystem.
San Francisco and the Silicon Valley represent a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. Applications for participation will be evaluated based on stage of development, industry validation, and relevancy to local industry interests. Elements of this program will be built to reflect the corporate objectives and therapeutic focus of participating companies.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.